← 홈

Antibody · 전립선암

16개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 16개
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab & Ipilimumab)

Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 61.3%임상시험 70상태 ACTIVE
AntibodyAstraZenecaPhase 2

durvalumab (Imfinzi, durvalumab and tremelimumab)

Prostate Cancer · HCC

#HCC#Antibody#Phase2#인기#항체+5
효능 ORR 48%임상시험 63상태 ACTIVE
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab monotherapy)

Advanced Metastatic Cancer; Advanced Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#Antibody#Phase2#인기#항체+5
효능 ORR 59%임상시험 57상태 RECRUITING
AntibodyTracon Pharmaceuticals Inc.Phase 2

Androgen receptor inhibitor (Androgen receptor inhibitor)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+4
임상시험 54상태 RECRUITING
Antibody3D Medicines (Sichuan) Co., Ltd.Phase 2

Envafolimab (Envafolimab)

Prostate Cancer; CDK12 Gene Mutation · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
임상시험 52상태 RECRUITING
AntibodyRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
AntibodystaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#항체#면역항체+4
임상시험 5상태 DISCONTINUED
AntibodystaleAmgenPhase 1

acapatamab (acapatamab)

Metastatic Castration-resistant Prostate Cancer; Prostate Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#Antibody#Phase1#항체#면역항체+3
임상시험 2상태 DISCONTINUED
AntibodystaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleCorvus Pharmaceuticals, Inc.Phase 1

atezolizumab (Tecentriq, Ciforadenant + atezolizumab)

Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleTranslational Oncology Research…Phase 2

Erlotinib + Bevacizumab (Erlotinib + Bevacizumab)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab Infusion [Opdivo])

Intermediate Risk Prostate Cancer; Castration-resistant Prostate Cancer · Intermediate Risk Prostate Cancer

#IntermediateRiskProstateCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 5%임상시험 1상태 DISCONTINUED
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab and Ipilimumab and Combination for Metastatic Cancer)

Advanced Metastatic Cancer; Advanced Prostate Cancer · Advanced Metastatic Cancer

#AdvancedMetastaticCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleRegeneronPhase 2

REGN15505+Cemiplimab (REGN15505+Cemiplimab)

Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) · Metastatic Castration-Resistant Prostate

#MetastaticCastration-ResistantPr#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleInstitut Cancerologie de l'OuestPhase 2

durvalumab (Imfinzi, SBRT + Durvalumab)

Node; Prostate; Bone Metastases · Node; Prostate

#NodeProstate#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

bevacizumab, bicalutamide and goserelin (bevacizumab, bicalutamide and goserelin)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE